In a randomised non-inferiority trial in children with AML, low-dose vs standard-dose induction chemotherapy gave similar CR/CRi rates (95.1% vs 95.3%) and 4-year overall survival (81.3% vs 83.6%), with faster neutrophil and platelet recovery.
RCT
Gao et al. Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial